By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Navidea Biopharmaceuticals 

425 Metro Place Northurt
Suite 400
Dublin  Ohio  43017  U.S.A.
Phone: 614-793-7500 Fax: 614 793 7520


Medical Device

Company News
Navidea Biopharmaceuticals (NAVB) Data For Manocept CD206 Targeting Platform Demonstrate Potential To Impact Tumor-Associated Macrophages And Kaposi‚Äôs Sarcoma Tumor Cells 4/22/2015 10:26:53 AM
Navidea Biopharmaceuticals (NAVB) Announces Lymphoseek Presentations At Upcoming Medical Conferences 4/15/2015 6:33:43 AM
Navidea Biopharmaceuticals (NAVB) Announces Presentation Of Lymphoseek Data At Society Of Surgical Oncology Meeting 3/25/2015 10:32:44 AM
Macrophage Therapeutics, A Subsidiary Of Navidea Biopharmaceuticals (NAVB), Executes Securities Purchase Agreement For $2.5 Million Financing And Receives Initial Funding 3/16/2015 10:59:31 AM
CLARIFICATION Of Navidea Biopharmaceuticals (NAVB) Announces Fourth Quarter And Full Year 2014 Results 3/5/2015 11:18:39 AM
Navidea Biopharmaceuticals (NAVB) And Norgine Enter European Commercial Partnership For Lymphoseek; Navidea To Receive $2 Million Upfront Payment 3/5/2015 11:01:23 AM
Macrophage Therapeutics, A Subsidiary Of Navidea Biopharmaceuticals (NAVB), Appoints Leading Experts To Therapeutics-Focused Scientific Advisory Board 2/27/2015 11:47:17 AM
Navidea Biopharmaceuticals (NAVB) To Announce Fourth Quarter And Year-End 2014 Financial Results On March 5, 2015 2/26/2015 11:47:23 AM
Navidea Biopharmaceuticals (NAVB) Release: Lymphoseek Data Presented In European Medical Conference Reinforces Clinical Value In Head & Neck Cancer Of The Oral Cavity 2/18/2015 10:44:54 AM
Navidea Biopharmaceuticals (NAVB) Release: Lymphoseek Results From Phase 3 Clinical Trial In Oral Cavity Cancer Of The Head And Neck Published In Annals Of Surgical Oncology 2/17/2015 10:59:42 AM